Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and effect on quality of life of weekly
paclitaxel plus bevacizumab as first line treatment in elderly patients (≥ 70 years old) with
metastatic breast cancer. Furthermore, the efficacy of the combination therapy will be
correlated with the functional status of patients according to the comprehensive geriatric
assessment.